Drugs / MK-8033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00559182 | Dec 2007 → Jun 2010 | cancer of unknown primary site | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00559182 ↗ |
| Known as | CPD 11R | ChEMBL registry synonym — accepted as the source's own label CHEMBL2323775 ↗ |
| Action | Inhibit | “Macrophage-stimulating protein receptor inhibitor” CHEMBL2323775 ↗1“MK-8033 is a small-molecule inhibitor of c-Met” PMID 29376210 ↗ Jan 2018 |
| Modality | Small molecule | “MK-8033 is a small-molecule inhibitor of c-Met” PMID 29376210 ↗ Jan 2018 |
| Route | Oral | “MK-8033 will be administered as an oral formulation” NCT00559182 ↗ |
| Target | MET | “MK-8033 is a small-molecule inhibitor of c-Met” PMID 29376210 ↗ Jan 2018 |
| Target | MST1R | “Macrophage-stimulating protein receptor inhibitor” CHEMBL2323775 ↗ |